Latest Articles

Publication Date
Integrated Bioinformatics and Experimental Analysis Revealed Crosstalk Between IL-6, Autophagy, Ubiquitination, and Key miRNAs in Female Infertility: Insights from Ovarian Endometriosis and Polycystic Ovary Syndrome.

Female infertility, affecting millions worldwide, involves complex molecular mechanisms such as chronic inflammation, impaired cellular death, and protein regulation. This study explores how the cytokine IL-6, the autophagy marker LC3, …

Published: Oct. 28, 2025, midnight
Fallopian tube cavernous haemangioma found during the caesarean section of a woman with a history of endometriosis: a case report and literature review.

This case report describes the management of fallopian tube cavernous haemangioma discovered at caesarean section, and provides insight to the literature on this extremely rare benign vascular tumor with regard …

Published: Oct. 28, 2025, midnight
Why the Women’s Health Space Needs to Expand Beyond Reproductive Health - MedCity News

Why the Women’s Health Space Needs to Expand Beyond Reproductive Health MedCity News

Published: Oct. 27, 2025, 10:24 p.m.
EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis - TipRanks

EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis TipRanks

Published: Oct. 27, 2025, 9:42 p.m.
Monday's Health Report: What is endometriosis and how can it affect your life? - WBRZ

Monday's Health Report: What is endometriosis and how can it affect your life? WBRZ

Published: Oct. 27, 2025, 9:02 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.
Polygala fallax Hemsl. Suppresses Malignant Phenotypes of Ectopic Endometrial Cells via the LINC02381-miR-27a-3p-EGFR Axis and PI3K/Akt Signaling - Frontiers

Polygala fallax Hemsl. Suppresses Malignant Phenotypes of Ectopic Endometrial Cells via the LINC02381-miR-27a-3p-EGFR Axis and PI3K/Akt Signaling Frontiers

Published: Oct. 27, 2025, 5:08 p.m.
Curcumol alleviates endometriosis via correcting the aberrant activation of Fas/RIPK1-mediated PANoptosis - Frontiers

Curcumol alleviates endometriosis via correcting the aberrant activation of Fas/RIPK1-mediated PANoptosis Frontiers

Published: Oct. 27, 2025, 4:10 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!